Floatz logo

Anti-Kras G12V Mtcr Pbl

Colon Cancer

National Cancer Institute (NCI)Cell therapyPhase 1/2Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
65/ 100

Competitive context

157 Active assets in the Colon Cancer cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Akeso
Phase 4A
Irinotecan
Fudan University
Phase 3BBB
Floxuridine
City of Hope Medical Center
Phase 2BBB
FLUOROURACILUM
Akeso
Phase 4BB
Eloxatin
Sun Yat-sen University
Phase 3BB

View all 50 →

Same molecule, other indications

Anti-Kras G12V Mtcr Pbl is also rated in:

digestive system cancerDormant
CC
Indicative ·
45 / 100
View asset →
rectal carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
gastric cancerDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →